Boryung Pharmaceutical
Korean pharma, cardiovascular fixed-dose combinations
003850 · KOSPI · South Korea
Public Market Listing
003850KOSPI
Live quotes, historical charts, and market capitalization for Boryung Pharmaceutical are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | AT1 receptor; NPC1L1; HMG-CoA reductaseSmall molecule | HypertensionAtherosclerotic Cardiovascular Disease |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (1)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | — | — | $170M | — | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $716M | — | $158M | — | report ↗ |
Boryung Pharmaceutical reported revenue of $716.05M, down 4.2% YoY and cash and equivalents of $157.61M for fiscal year 2025.
Figures only: this period's report disclosed no narrative text